On Thursday, Harman International Industries Inc./DE/(NYSE:HAR)’s shares declined -7.00% to $130.38.
Harman International Industries Inc./DE/(HAR) declared a cash dividend on April 30, 2015 of $0.33 cents per share for the quarter ended March 31, 2015. The quarterly dividend will be paid on May 26, 2015, to each stockholder of record as of the close of business on May 11, 2015.
Harman International Industries, Incorporated develops, manufactures, and markets audio products, lighting solutions, and electronic systems, in addition to digitally integrated audio and infotainment systems for the automotive industry worldwide. Its Infotainment segment offers infotainment systems for vehicle applications to be installed primarily as original equipment by automotive manufacturers.
Pernix Therapeutics Holdings Inc (NASDAQ:PTX)’s shares dropped -7.00% to $6.38.
Pernix Therapeutics Holdings Inc (PTX) declared financial results for the first quarter ended March 31, 2015.
Highlights of and subsequent to the quarter:
- Attained the Zohydro ER franchise from Zogenix, Inc. for $80.9 million in upfront cash, about 1.7 million shares of Pernix common stock, and potential regulatory and commercial milestone payments.
- Raised $130 million of gross proceeds through a private offering of 4.25% Convertible Senior Notes due 2021, funding the cash portion of the Zohydro® ER franchise acquisition and strengthening the Company’s balance sheet.
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells branded and generic pharmaceutical products. The companys product comprise CEDAX, an oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; Zutripro, Rezira, and Vituz for the relief of cough and nasal congestion; and OMECLAMOX-PAK a gastroenterology product.
At the end of Thursday’s trade, Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB)‘s shares dipped -6.90% to $1.35.
Navidea Biopharmaceuticals Inc (NAVB) declared that the Company will report its financial results for the first quarter 2015, on Tuesday, May 12, 2015 proceeding to a conference call with the investment community, planned at 8:30 a.m. EDT.
Navidea Biopharmaceuticals, Inc., a precision medicine company, focuses on the development and commercialization of precision diagnostics, therapeutics, and radiopharmaceutical agents.
PAREXEL International Corporation (NASDAQ:PRXL), ended its Thursday’s trading session with -6.86% loss, and closed at $63.58.
PAREXEL International Corporation (PRXL) stated financial results for the third quarter of Fiscal Year 2015, which ended on March 31, 2015.
Third Quarter Fiscal Year 2015 Results
For the three months ended March 31, 2015 PAREXEL’s merged service revenue raised by 2.0% to $502.0 million contrast with $492.4 million in the preceding year period. Revenue grew 5.1% on a constant currency basis, not taking into account the negative impact of foreign currency exchange rate movements of $15.4 million. Operating income as stated under Generally Accepted Accounting Principles (GAAP) totaled $54.2 million, or 10.8% of service revenue, in the third quarter of Fiscal Year 2015, as contrast with $52.2 million, or 10.6% of service revenue, in the comparable quarter of the preceding year. GAAP net income for the quarter totaled $37.7 million, or $0.68 per diluted share, contrast with GAAP net income of $34.7 million, or $0.60 per diluted share for the quarter ended March 31, 2014. GAAP diluted earnings per share grew 13.3% year-over-year.
PAREXEL International Corporation, a biopharmaceutical outsourcing services company, provides clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
